期刊文献+

磺达肝癸钠在ST段抬高心肌梗死患者中的应用:药物、策略、环境或皆而有之? 被引量:1

Fondaparinux in ST-Segment Elevation Myocardial Infarction The Drug, the Strategy, the Environment, or All of the Above?
下载PDF
导出
摘要 抗栓治疗已成为应对动脉粥样硬化威胁的主要手段,而“动脉粥样硬化血栓形成”则成为心血管领域普遍接受的名称。可以理解,动脉粥样硬化血栓形成的生物学研究已导致多种阻断凝血途径药物的开发,从而预防动脉血栓形成。JAMA杂志中报道的OASIS(Organization to Assess Strategies for Ischemic Syndromes)-6研究代表了该领域又一个重要的里程碑。
出处 《美国医学会杂志(中文版)》 2007年第2期116-117,共2页 The Journal of the American Medical Association(Chinese Edition)
  • 相关文献

参考文献7

  • 1OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial. JAMA. 2006;295:1519-1530.
  • 2Rajagopal V, Bhatt DL. Factor Xa inhibitors in acute coronary syndromes: moving from mythology to reality. J Thromb Haemost. 2005;3:436-438.
  • 3CREATE Trial Group Investigators. Effects of reviparin, a low-molecularweight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA. 2005;293:427-436.
  • 4Weaver WD, Simes R J, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review.JAMA. 1997;278:2093-2098.
  • 5Simoons ML, Bobbink IW, Boland J, et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) study. J Am Coll Cardiol. 2004;43:2183- 2190.
  • 6Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108-3116.
  • 7Califf RM, Peterson ED, Gibbons R J, et al.Integrating quality into the cycle of therapeutic development. J Am Coll Cardiol. 2002;40:1895-1901.

同被引文献9

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部